Impact of tisagenlecleucel product attributes on clinical outcomes in pediatric and young adult patients with relapsed or refractory acute lymphoblastic leukemia (r/r ALL).

被引：0
|
作者：
Gershgorin, Irina [1 ]
Waldron, Edward R. [1 ]
Grupp, Stephan A. [2 ]
Levine, John E. [3 ]
Pulsipher, Michael A. [4 ]
Davies, Stella M. [5 ]
Myers, G. Doug [6 ]
Jeschke, Margit [7 ]
Engels, Boris [8 ]
del Corral, Chris [1 ]
Baruchel, Andre [9 ,10 ]
机构：
[1] Novartis Pharmaceut, E Hanover, NJ USA
[2] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA
[3] Univ Michigan, Ann Arbor, MI 48109 USA
[4] Childrens Hosp Los Angeles, Keck Sch Med USC, Los Angeles, CA 90027 USA
[5] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA
[6] Childrens Mercy Hosp, Kansas City, MO 64108 USA
[7] Novartis Pharma AG, Basel, Switzerland
[8] Novartis Inst BioMed Res, Cambridge, MA USA
[9] Hop Univ Robert Debre, AP HP, Paris, France
[10] Univ Paris, Paris, France
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
510
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Pharmacokinetics/pharmacodynamics (PKPD) of blinatumomab in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL).
    Zhu, Min
    Kratzer, Andrea
    Johnson, Jessica
    Holland, Chris
    Brandl, Christian
    Singh, Indrajeet
    Wolf, Andreas
    Doshi, Sameer
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [32] Obesity Associates with Inferior Outcomes and Toxicity in Pediatric and Young Adult Patient with Relapsed/ Refractory B-Cell Acute Lymphoblastic Leukemia Treated with Commercially Manufactured Tisagenlecleucel
    Ross, Anthony J.
    Baggott, Christina
    Prabhu, Snehit
    Pacenta, Holly
    Philips, Christine
    Rossoff, Jenna
    Stefanski, Heather E.
    Talano, Julie
    Moskop, Amy
    Baumeister, Susanne H. C.
    Verneris, Michael R.
    Myers, Gary Douglas
    Karras, Nicole
    Qayed, Muna
    Hermiston, Michelle L.
    Satwani, Prakash
    Krupski, Christa
    Keating, Amy K.
    Wilcox, Rachel
    Fabrizio, Vanessa A.
    Chinnabhandar, Vasant
    Curran, Kevin J.
    Mackall, Crystal L.
    Laetsch, Theodore W.
    Althouse, Sandra K.
    Maude, Shannon L.
    Henry, Curtis J.
    Schultz, Liora M.
    Skiles, Jodi L.
    BLOOD, 2022, 140 : 10419 - 10421
  • [33] Phase 2 Study of Blinatumomab in Japanese Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL)
    Kobayashi, Yukio
    Zimmerman, Zachary F.
    Oh, Iekuni
    Maeda, Yoshinobu
    Minami, Hironobu
    Miyamoto, Toshihiro
    Sakura, Toru
    Iida, Hiroatsu
    Chen, Yuqi
    Kiyoi, Hitoshi
    BLOOD, 2018, 132
  • [34] Leukapheresis and Tisagenlecleucel Manufacturing Outcomes in Patients Age <3 Years with Relapsed/Refractory Acute Lymphoblastic Leukemia
    Fong, David
    Tiwari, Ranjan
    Acker, Christopher
    Clough, Lee
    Willert, Jennifer
    TRANSPLANTATION AND CELLULAR THERAPY, 2023, 29 (09): : 579.e1 - 579.e10
  • [35] Preliminary results of novel safety interventions in adult patients (pts) with relapsed/refractory acute lymphoblastic leukemia (R/R ALL) in the ZUMA-3 Trial
    Shah, B.
    Stock, W.
    Wierda, W.
    Topp, M.
    Kersten, M. J.
    Houot, R.
    Boissel, N.
    Holmes, H. E.
    Schiller, G. J.
    Mardiros, A.
    Rossi, J.
    Jiang, Y.
    Shen, T.
    Aycock, J.
    Stout, S.
    Wiezorek, J.
    Jain, R.
    ANNALS OF ONCOLOGY, 2017, 28
  • [36] Salvage Chemotherapy with Inotuzumab Ozogamicin (INO) Combined with Mini-Hyper-CVD for Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)
    Sasaki, Koji
    Kantarjian, Hagop M.
    O'Brien, Susan
    Thomas, Deborah A.
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Kadia, Tapan
    Jain, Nitin
    Konopleva, Marina
    Estrov, Zeev
    Takahashi, Koichi
    Khouri, Maria R.
    Jacob, Jovitta
    Garris, Rebecca
    Cortes, Jorge E.
    Jabbour, Elias
    BLOOD, 2015, 126 (23)
  • [37] ANALYSIS OF SAFETY DATA FROM 2 MULTICENTER TRIALS OF CTL019 IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED/REFRACTORY (R/R) B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)
    Maude, S. L.
    Grupp, S. A.
    Pulsipher, M. A.
    Rives, S.
    Myers, G. D.
    Verneris, M. R.
    Buechner, J.
    Laetsch, T. W.
    Bittencourt, H.
    Boyer, M.
    De Moerloose, B.
    Qayed, M.
    Davies, S.
    Martin, P. L.
    Bader, P.
    Schlis, K.
    Wood, P.
    Taran, T.
    Zhang, Y.
    Leung, M.
    June, C. H.
    Levine, J.
    HAEMATOLOGICA, 2017, 102 : 197 - 198
  • [38] More Updates to Come of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial: Could the Statistical Methodology Be Further Improved? Reply
    Laetsch, Theodore W.
    Tiwari, Ranjan
    Grupp, Stephan A.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (13)
  • [39] Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia in Adult Patients
    Oriol, Albert
    ACTA HAEMATOLOGICA, 2015, 133 (01) : 89 - 90
  • [40] Immunogenicity of tisagenlecleucel in relapsed/ refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL) patients.
    Mueller, Karen Thudium
    Grupp, Stephan A.
    Maude, Shannon L.
    Levine, John E.
    Pulsipher, Michael
    Boyer, Michael W.
    August, Keith Jason
    Myers, Gary Douglas
    Awasthi, Rakesh
    Waldron, Edward K.
    Bubuteishvili-Pacaud, Lida
    Taran, Tanya
    Cota, Mariana
    Tam, Constantine Si Lun
    Jager, Ulrich
    Foley, Ronan
    Borchmann, Peter
    Schuster, Stephen J.
    Waller, Edmund K.
    Laetsch, Theodore Willis
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345